DM
VNDA icon

Diker Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Diker Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Hold
21,880
– – 0.1% 44
2026
Q1 		$151K Buy
+21,880
New +$169K 0.13% 40

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diker Management's VNDA Position: Q2 2026 in Review

Diker Management held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 21,880 shares worth $134K. The position accounts for 0.1% of the portfolio, ranked #44.

Diker Management first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $151K in Q1 2026. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Diker Management held 21,880 shares of Vanda Pharmaceuticals worth $134K as of Q2 2026.
  • Diker Management left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
  • Vanda Pharmaceuticals made up 0.1% of Diker Management's portfolio in Q2 2026, its #44 holding.
  • Diker Management first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Diker Management's Vanda Pharmaceuticals position peaked at $151K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Diker Management's 13F filing for Q2 2026, filed 14 Aug 2026.